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Introduction: Bone metastasis is the most common complication of advanced breast cancer. The associated
cancer-induced bone disease is treated with bone-sparing agents like zoledronic acid. Clinical trials have
shown that zoledronic acid also reduces breast cancer recurrence in bone; potentially by modifying the bone
microenvironment surrounding disseminated tumour cells.We have characterised the early effects of zoledronic
acid on key cell types of the metastatic niche in vivo, and investigated how these modify the location of breast
tumour cells homing to bone.
Methods: Femalemicewere treatedwith a single, clinically achievable dose of zoledronic acid (100 μg/kg) or PBS.
Bone integrity, osteoclast and osteoblast activity and number/mm trabecular bone on 1, 3, 5 and 10 days after
treatment were assessed using μCT, ELISA (TRAP, PINP) and bone histomorphometry, respectively. The effect
of zoledronic acid on osteoblasts was validated in genetically engineered mice with GFP-positive osteoblastic
cells. The effects on growth plate cartilage were visualised by toluidine blue staining. For tumour studies, mice
were injected i.c. with DID-labelled MDA-MB-231-NW1-luc2 breast cancer cells 5 days after zoledronic acid
treatment, followed by assessment of tumour cell homing to bone and soft tissues by multiphoton microscopy,
ﬂow cytometry and ex vivo cultures.
Results: As early as 3 days after treatment, animals receiving zoledronic acid had signiﬁcantly increased trabec-
ular bone volume vs. control. This rapid bone effect was reﬂected in a signiﬁcant reduction in osteoclast and
osteoblast number/mm trabecular bone and reduced bone marker serum levels (day 3–5). These results were
conﬁrmed in mice expressing GFP in osteoblastic linage cells. Pre-treatment with zoledronic acid caused accu-
mulation of an extra-cellular matrix in the growth plate associated with a trend towards preferential [1] homing
of tumour cells to osteoblast-rich areas of bone, but without affecting the total number of tumour cells. The
number of circulating tumour cells was reduced in ZOL treated animals.
Conclusion: A single dose of zoledronic acid caused signiﬁcant changes in the bone area suggested to contain the
metastatic niche. Tumour cells arriving in this modiﬁed bone microenvironment appeared to preferentially
locate to osteoblast-rich areas, supporting that osteoblasts may be key components of the bone metastasis
niche and therefore a potential therapeutic target in breast cancer.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).matrix; GFP, Green ﬂuorescent
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The majority of cancer deaths are due to metastatic disease, and the
lack of effective anti-metastatic therapies reﬂects our incomplete un-
derstanding of the underlying biology of tumour cell spread. Breast,
prostate and lung cancers are amongst the most common malignancies
with a preference to metastasise to the skeleton [1]. Treatment at this
stage is palliative and often includes a bone-sparing anti-resorptive
bisphosphonate (BP) [2], with zoledronic acid being the most potent
[3]. In breast cancer, the dissemination of malignant cells to bone is
thought to be an early event and tumour cells may reside in a dormant
state within the bone for many years before developing into thethe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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tumour cell dormancy, as well as the triggers for escape to a prolifera-
tive state, is currently one of the most intensely studied areas of cancer
biology.
There is a general consensus that components of the bone marrow
microenvironment make up a ‘bone metastasis niche’, responsible for
regulating tumour cell homing, survival and dormancy. To what extent
this overlaps with the hematopoietic stem cell niche, a specialised
microenvironment that regulates hematopoietic stem cell (HSC) func-
tion, survival and quiescence, is not fully established [5–7]. The HSC
niche is described to include an endosteal niche, of which the main
cellular components are cells of the osteoblastic lineage [8]. In addition
to regulating HSCs, it is proposed that the same niche may be creating a
beneﬁcial microenvironment for disseminated tumour cells in bone.
Using in vivomodel systems, Shiozawa et al. have shown that prostate
cancer cells and HSCs reside within the same niche in the bonemarrow
[7] and that disseminated tumour cells can displaceHSCs from theniche
resulting in growth of metastatic colonies [9,10]. This suggests that
components of the HSC niche, including osteoblastic cells, may be
involved in tumour cell homing to bone. However, it remains to be
established whether the osteoblast is a critical component of the meta-
static niche, as well as the speciﬁc role of the tightly coupled osteoclast.
In a breast cancer xenograft model, we have demonstrated that both
osteoblast and osteoclast number/mm trabecular bone surface is signif-
icantly altered by breast tumour colonies at early and advanced stages
of bone metastasis, indicating that both cell types may be intimately
linked to tumour progression [11].
Therapeutic targeting of the bone microenvironment with anti-
resorptive agents is standard of care for breast cancer patients with
established cancer-induced bone disease [2]. Intriguing data from the
AZURE trial demonstrated increased survival and reduced bone metas-
tases when zoledronic acid is given in the adjuvant setting [12]. Several
in vivo studies have also reported that inhibiting osteoclastic bone
resorption with BPs early in the development of bone metastases
reduces cancer-induced bone disease and may slow down disease pro-
gression. Preventive treatment with BPs (prior to tumour cell injection)
is shown to be more effective at reducing tumour growth in bone when
compared to therapeutic scheduling (initiated once bonemetastases are
established). For example, ibandronate treatment (10 μg/kg/day) of
animals with established intrafemoral MDA-MB-231 tumours reduced
progression of osteolytic lesions and metastases but did not eliminate
tumour growth and larger lesions were unaffected [13]. In contrast,
when treatment was initiated prior to cancer cell injection (day−3),
formation of newosteolytic lesions and incidence ofmetastaseswere re-
duced. Alterations to the metastatic site before tumour cell arrival may
thus impede tumour cell engraftment in bone, which could result in
more pronounced anti-tumour effects. Another study suggesting that
the reported anti-tumour effects of bisphosphonates are due to alter-
ations of the bonemicroenvironment showed that preventive treatment
with olpadronate (1.6 μmol/kg/day, 2 days beforeMDA-MB-231 tumour
cell injection) signiﬁcantly reduced new bone metastasis formation,
while a therapeutic protocol (1.6 μmol/kg/day, day 28 to day 46) did
not affect tumour growth in bone [14]. The authors suggest that the pre-
ventive schedule reduced tumour growth by inhibiting the release of
tumour growth factors by osteoclastic bone resorption, an established
mechanism for driving progression of cancer-induced bone disease.
Most studies investigating BP-induced anti-tumour effects did not in-
vestigate the consequences of inhibiting osteoclast activity on the tightly
coupled osteoblasts. As both cell types are now suggested to be part of
the metastatic niche, it is of great interest to determine how preventive
scheduling of anti-resorptive agents modify osteoblasts, and the poten-
tial implications for subsequent tumour cell homing and colonisation. It
is possible that development of bone metastases is also inhibited by
BPsmodifying the size and/or availability of themetastatic (osteoblastic)
niche. The available data on the potential direct vs. indirect effects of
bisphosphonates on osteoblasts is somewhat contradictory, with studiesreporting a reduction of osteoblast activity and survival in vitro and
in vivo [15–18] while others have reported a beneﬁcial effect of NBP
treatment on osteoblast development, survival and growth [19–21].
We hypothesise that modiﬁcation of the cellular components of
the bone metastasis niche by zoledronic acid may affect the ability of
tumour cells to initiate bone metastasis. Here we present the ﬁrst
in vivo study to assess the early (days 1–10) effects of a single, clinically
relevant, dose of zoledronic acid on the bone microenvironment
suggested to be part of the bone metastatic niche, osteoblasts and
osteoclasts. In addition, we determined how these rapid, zoledronic
acid-induced, changes to the bone microenvironment may affect early
colonisation of particular areas of bone by breast cancer cells.
Materials and methods
Animal models and drug treatment
BALB/cAnNCrl Foxn1nu/nu immunocompromised (athymic nude)
mice were obtained from Charles River (Kent, UK). A transgene
engineered to express GFP under the control of type 1 collagen promoter
(pOBCol2.3GFPemd, kindly provided by Prof. David Rowe, University
of Connecticut, USA) was introduced into the BALB/cAnNCrl nude mice
by repeated backcrossing to generation N5. Heterozygous nude mice
were then intercrossed to generate homozygotes. This line (BALB/
cAnNCrl.Cg-Tg(Col1a1-GFP)Row Foxn1nu/nu) results in immunocompro-
mised mice expressing GFPemd in cells of the osteoblast lineage and
was used as amodel to investigate the link between disseminated cancer
cells and resident osteoblasts. Micewere housed in a controlled environ-
ment with a 12 h light/dark cycle at 22 °C. They were provided with ad
libitum access 2018 Teklad Global 18% protein rodent diet containing
1.01% Calcium (Harlan Laboratories, UK) in individually ventilated
cages (Tecniplast, Milan, Italy). All in vivo experiments complied with
the UK Animals (Scientiﬁc Procedures) Act 1986 and were reviewed
and approved by the local Research Ethics Committee of the University
of Shefﬁeld (Shefﬁeld, UK). All work was performed under Home Ofﬁce
regulations (project licenses 40/3462 and 40/3531).
Cohorts of 6- and 12-week old female immunocompetent BALB/c or
6-week old immunocompromised BALB/c nude mice (n= 2–7/group)
were used to assess the effect of zoledronic acid treatment on bone
cells. To investigate the effects on osteoblasts in greater detail 6- and
10-week-old transgenic male mice (n = 2/group) expressing GFP-
positive osteoblastic cells on a BALB/c nude background (described
above) were used.
Animals were randomised into two treatment groups: (1) PBS and
(2) zoledronic acid (ZOL, 100 μg/kg i.p.; supplied as disodium salt
by Novartis; equivalent to the 4 mg infusion used in the treatment of
cancer-induced bone disease) and sacriﬁced on days 0, 1, 3, 5 and 10
post injection (Fig. 1A). Hind legs were collected and ﬁxed in either
10% buffered formalin prior to μCT analysis or 4% PFA solution before
decalciﬁcation (0.5 M EDTA, 0.5% PFA, PBS, pH 8). Blood was collected
and spun down at 4000 rpm for 10 min at 4 °C and serum was stored
at−80 °C prior to analysis of serum bone turnover markers.
Bone metastasis model
To assess the effect of pre-treatment with ZOL on tumour cell hom-
ing to bone 8–13-week old female BALB/cmice (heterozygote or homo-
zygote nude) with GFP expressing cells of the osteoblast linage were
injected with PBS or ZOL (100 μg/kg i.p.) on day 0. Animals were
injected with 1 × 105 MDA-MB-231-NW1 (luc2 positive) breast cancer
cells intracardiac and sacriﬁced on day ten (Fig. 1B). Immediately before
injection, tumour cells were labelled with the lipophilic dye DID (Life
Technologies, Paisley, UK) according to the manufacturer's instructions.
Whole blood was collected, all samples from one treatment groupwere
pooled, red blood cells were lysed, and the number of DID positive
(DID+) tumour cells/mL was determined by ﬂow cytometry. Bone
Fig. 1. In vivo studies, experimental outline. (A) Immunocompetent 6- or 12-week old balb/c (n= 2–7/treatment group and time point) or immunocompromised 6-week old balb/c nude
mice (n = 3/day PBS, n = 4/day ZOL) were injected intraperitoneally with a single dose of ZOL (100 μg/kg) or PBS on day 0 and sacriﬁced on the days indicated by white/black
arrowheads. (B) Genetically engineered balb/c (heterozygote or homozygote nude) with GFP expressing cells of the osteoblast lineage received the same treatment and were injected
with 1 × 105 MDA-MB-23-NW1 breast cancer cells i.c. on day 5 before sacriﬁce on day 10 (n= 4/treatment group, 2 repeats). (C) Schematic description of the areas used for analysis
of bone cells on trabecular and cortical surfaces.
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treatment group, red blood cells were lysed and the number of DID+
tumour cells was determined by ﬂow cytometry. To assess tumour cell
growth, the remaining cell suspensions were plated into 6-well plates
containing DMEM + GlutaMAX + Pyruvate supplemented with
10%FCS, 5% Pen Strep, 5% fungizone, and 1 mg/mL G418. In addition
brain, liver, lung, spleen and kidneys were mechanically disrupted,
passed through a 100 μm cell strainer and plated into 6-well plates. Ex
vivo cultures were left to grow for 14 days and media were changed
every 2 days before visualisation of bioluminescence using IVIS.
Multiphoton microscopy
Tibias were snap-frozen in liquid nitrogen and embedded into
Cryo-M-Bed (Bright Instrument Co. Ltd, Huntingdon, UK). The
growth plate was exposed using a Bright OTF Cryostat and a 3020
microtome (Bright Instrument Co. Ltd, Huntingdon, UK). A stack
area of 2104 μm × 2525 μm with 70 μm depth was captured with a
Zeiss LSM510 NLO upright multiphoton/confocal microscope (Carl
Zeiss Inl, Cambridge, UK). For detection of tumour cells in bone we
visualised the DID-labelled cancer cells (DID+ events) using a
633 nm laser. Because the size of the DID+ events was variable we
were unable to directly correlate the number of events with the
number of tumour cells in bone. Bone matrix was visualised by
second harmonic generation using a multiphoton laser at 900 nm
(Coherent, Santa Clara, CA.). Quantiﬁcation of DID+ events within
selected regions of interest was analysed using the Volocity 3D Image
Analysis software 6.01 (PerkinElmer, Cambridge, UK).
Microcomputed tomography imaging
Microcomputed tomography analysis of proximal tibias and distal
femurs was performed using a Skyscan 1172 X-ray computedtomography (Skyscan) as reported previously [11]. Trabecular bone
volume (BV/TV in %), number (Tb.N. in mm−1) and cortical bone vol-
ume (mm3) for tibias and femurs were calculated covering 1 mm,
starting from the lowest part of the growth plate.
Osteoclast and osteoblast quantiﬁcation
Osteoclasts and osteoblasts were quantiﬁed on histological sections
following TRAP or H&E staining, respectively. TRAP staining of osteo-
clasts on histological sections (3 μm) and identiﬁcation of osteoblasts
using morphological criteria were done as previously described [11].
Osteoclast and osteoblast number/mm trabecular bone surface was
then scored on two non-serial sections using a Leica RMRB upright mi-
croscope, a 10× objective and OsteoMeasure software (Osteometrics).
In order to determine bone cell number per mm/trabecular bone all
trabecular surfaces 125 μm away from the growth plate were scored
excluding the cortical bone surfaces. For cortical bone analysis scoring
of osteoblasts lining the cortical surface was started 125 μm away
from the growth plate and was performed for 1500 μm (Fig. 1C).
GFP immunohistochemistry
GFP expressing osteoblastic cells were identiﬁed by immunohisto-
chemistry using an antibody speciﬁc to GFP. Dewaxed sections were
incubated in 0.9% H2O2 for 10 min at ambient temperature prior to
washing in dH2O and PBS. Sections were transferred to 10% normal
goat serum (Vector Laboratories, S1000) in PBS for 30 min followed
by overnight incubation at 4 °C with the primary antibody (anti-GFP
rabbit IgG fraction polyclonal, Invitrogen, A11122, 1:600 in 5% normal
goat serum). Slides were washed and incubated with the secondary
antibody (goat anti-rabbit HRP, Insight Biotec, SC2004; 1:400 in PBS)
for 45 min at ambient temperature. GFP was visualised using VECTOR
NovaRED Peroxidase solution (Vector laboratories, Kit SK-4800).
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The metachromasia dye toluidine blue was used to stain acidic pro-
teoglycan present in the growth plate of tibias. Dewaxed and hydrated
histological sections were immersed in toluidine blue working solution
(Toluidine Blue O, Sigma Aldrich; 1% NaCL pH= 2.3) for 3 min at ambi-
ent temperature. Sections were then washed in dH2O, dehydrated and
cover slipped.
Osteoclast and osteoblast activity measured by ELISA
Osteoclast-derived tartrate-resistant acid phosphatase form 5b
(TRACP 5b) in serum was measured using the MouseTRAP™ Assay
(Immunodiagnosticsystems) and Rat/Mouse PINP Enzyme immu-
noassay for N-terminal propeptide of type I procollagen (PINP,
Immunodiagnosticsystems) was used to determine osteoblast activity,
both according to the manufacturer's instructions.Trabcular Bone Volume
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Fig. 2. Effects of a single dose of zoledronic acid onbone architecture. μCT analysiswasperformed
volume and architecture. Proximal tibia (A,B) and distal femur (D,E) were analysed for trabecu
Representative cross sections of tibae are shown in (C). Two-way ANOVA and Bonferroni po
5 day 10: n= 5 for each time point and treatment group. All graphs show mean ± SEM.Statistical analysis
Statistical analysis was performed using Prism GraphPad (Version
5.0). Analysis was done by Student's t-test or two-way ANOVA and
Bonferroni post-test. The applied test is indicated in each ﬁgure legend.
A p-value of p b 0.05 was considered signiﬁcant.Results
A single dose of zoledronic acid induces early changes to bone volume and
structure
In order to establish how quickly bone structure and volume were
affected in young (6-week old) animals, we characterised the effects
of a single dose of zoledronic acid (100 μg/kg, ZOL) or PBS 1, 3, 5 and
10 days post treatment by μCT analysis.Day 1 Day 3 Day 5 Day 10
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to assess the immediate effects of a single dose of zoledronic acid (100 μg/kg, i.p.) on bone
lar bone (A, D) expressed as % bone volume/tissue volume and trabecular number (B,E).
st-test: ****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01. Day 1: n = 7, day 3: n = 7, day 5: n =
244 M.-T. Haider et al. / Bone 66 (2014) 240–250ZOL caused a signiﬁcant increase in trabecular bone volume of prox-
imal tibias from day 3 onwards when compared to control animals
(PBS: 15.67% vs. ZOL: 18.92%; p ≤ 0.01; Fig. 2A). This increase was
less prominent on day 5 but remained signiﬁcantly elevated at day 10
(PBS: 15.35% vs. ZOL: 20.88%; p≤ 0.0001; Fig. 2A). ZOL also signiﬁcantly
increased trabecular number by day 10 (PBS: 3.27 mm−1 vs. ZOL:
4.45mm−1; p≤ 0.01; Fig. 2B)when compared to PBS treatment. Repre-
sentative cross sections of the proximal tibia illustrating this effect are
shown in Fig. 2C.
Similarly, trabecular bone volume in the distal femur increased
signiﬁcantly compared to control 10 days after ZOL administration
(PBS: 22.8% vs. ZOL: 31.72%; p ≤ 0.001; Fig. 2D). Trabecular number
was increased from day 5 up to 10 days post treatment (day 5: PBS:
5.11 mm−1 vs. ZOL: 6.47 mm−1; p ≤ 0.05; day 10: PBS: 4.88 mm−1
vs. ZOL: 7.10 mm−1; p ≤ 0.001; Fig. 2E).
These results clearly demonstrate that in young animals with high
bone turnover, administration of a single, clinically relevant, dose of
ZOL causes a rapid and signiﬁcant increase in bone volume that is main-
tained for at least 10 days.Fig. 3. Zoledronic acid-induced effects on osteoclasts and osteoblasts. (A) Tartrate-resistant alka
centration in serum samples of 6-week old female balb/c mice treated with a single dose of 10
osteoclast and osteoblast activity, respectively (n= 5/time point and treatment group). (C) Os
on TRAP-stained histological sections. (D) Osteoblasts (Ob) per mm trabecular bone surface w
stained sections of proximal tibias. Scale bar = 100 μm, 20× magniﬁcation. Example images f
50 μm. Arrows indicate rows of osteoblasts; stars indicate TRAP-positive osteoclasts (red). Day
for ZOL. Two-way ANOVA and Bonferroni post-test: ****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, *Zoledronic acid treatment induces rapid effects on bone cell activity and
number/mm trabecular surface
We next established whether ZOL treatment also alters the number
and activity of osteoblasts and osteoclasts, cell types suggested to be
important for breast cancer progression in bone. For the analysis of
osteoblast and osteoclast numbers per mm bone surface we focused
on trabecular bone, as the majority of MDA-MB-231 tumours appear
to originate in the trabeculae rich metaphysis area [11,22].
As early as three days after administration there was a signiﬁcant
reduction in osteoclast activity in ZOL treated animals compared to
control, measured by serum TRAP concentration (PBS: 7.26 U/L vs.
ZOL: 3.22 U/L; p ≤ 0.01; Fig. 3A). This effect was transient and
TRAP levels in the ZOL group started to increase again by day 5. The
effect of the bisphosphonate on osteoclasts was further conﬁrmed
with the detection of a signiﬁcant reduction in the osteoclast number
on trabecular bone surfaces 3 days after ZOL injection compared to
control (PBS: 4.97 vs. ZOL: 1.20; p ≤ 0.01; Fig. 3C). The osteoclast
number started to normalise to control levels on day 5. We also detectedline phosphatase (TRAP) and (B) N-terminal propeptide of type I procollagen (PINP) con-
0 μg/kg ZOL or PBS were analysed 1, 3, 5 and 10 days after injection in order to determine
teoclasts (Oc) per mm trabecular bone surface and (G) osteoclast size inmm2 were scored
ere scored on H&E stained sections of the right tibia. (E) Representative images of TRAP
or osteoclast size difference post ZOL vs. PBS treatment are illustrated in (F). Scale bar =
1: n= 7, day 3: n= 6, day 5: n= 7, day 10: n= 6 for PBS and n= 5 for all time points
p ≤ 0.05. All graphs showmean ± SEM.
245M.-T. Haider et al. / Bone 66 (2014) 240–250an increase in osteoclast size as early as 24 h after ZOL administration
when compared to mice receiving PBS, which reached signiﬁcance at
day 3 (PBS: 7.99 × 10−05 mm2 vs. ZOL: 1.89 × 10−04 mm2, p ≤ 0.001,
Fig. 3F and G).
Osteoclasts were not the only bone cells affected by ZOL treatment.
Osteoblast activity, measured by determining the serum levels of
the bone formation marker PINP, decreased signiﬁcantly 3 days post
treatment in the ZOL group compared to control (PBS: 106.46 ng/mL
vs. ZOL: 40.52 ng/mL; p ≤ 0.05; Fig. 3B). Changes in the osteoblast
number were in line with the PINP measurements; showing a sudden
decrease in osteoblast number/mm trabecular bone in ZOL treated
mice compared to control on day 3 (PBS: 9.00 vs. ZOL: 3.71; p b 0.01;
Fig. 3D). Osteoblasts decreased further 5 days post treatment (PBS:
10.44 vs. ZOL: 1.56; p ≤ 0.0001; Fig. 3D) followed by a slight increase
on day 10. In a small subset of samples (n = 4/treatment group,
day 5) we also analysed the number of osteoblasts/mm cortical bone,
and found no signiﬁcant reduction in osteoblasts on either medial or
lateral bone surfaces when comparing the ZOL group to control mice
(medial: PBS: 28.37 vs. ZOL: 22.71, p = 0.4482; lateral: PBS: 56.66 vs.
ZOL: 45.81, 0.6101, data not shown).
These data show that the rapid ZOL-induced increase in bone
volume is a result of effects on both osteoblasts and osteoclasts on tra-
becular bone surfaces.Effects of a single dose of zoledronic acid on bone in immunocompromised
mice
We repeated the experiment using immunocompromised animals
required for xenograft models of breast cancer metastasis to bone.
In agreement with the previous results, trabecular bone volume
of tibias in the ZOL group was signiﬁcantly increased on days 3 and
10 after treatment when compared to control (day 3: PBS: 7.21% vs.
ZOL: 13.40%; p ≤ 0.01; day 10: PBS: 11,24% vs. ZOL: 17.24%; p ≤
0.05; Fig. 4A). The trabecular number signiﬁcantly increased as
early as 3 days post ZOL treatment (day 3: PBS: 2.25 mm−1 vs. ZOL:Fig. 4. Effects of ZOL treatment on bone and bone cells in immunocompromised mice. Female
effects of the drug on (A) trabecular bone volume, (B) trabecular number, (C) osteoclast activity
(E) osteoblast activitymeasured in serumusing PINP ELISAand (F) osteoblast number permm tr
and 4/day ZOL; for TRAP and PINP day 5: n= 4/group. Two-way ANOVA and Bonferroni post-3.65 mm−1; p ≤ 0.05; day 10: PBS: 2.49 mm−1 vs. ZOL: 4.81 mm−1;
p ≤ 0.01; Fig. 4B).
The effects of ZOL on osteoclast activity detected in immunocompe-
tent animals were also conﬁrmed, with a signiﬁcant reduction in serum
TRAP levels at 3 and 5 but not 10 days post ZOL injection when com-
pared to control (day 3: PBS: 7.18 U/L vs. ZOL: 2.46 U/L p ≤ 0.001; day
5: PBS: 5.70 U/L vs. ZOL: 1.97 U/L; p ≤ 0.01; Fig. 4C). Furthermore, a
reduction in osteoclast number per mm trabecular surface was ob-
served from day 3 onwards (day 3: PBS: 7.30 vs. ZOL: 0.46 and day 5:
PBS: 8.35 vs. ZOL: 0.88 both p ≤ 0.0001; day 10: PBS: 7.05 vs. ZOL:
2.40, p ≤ 0.001; Fig. 4D) which was mirrored by the bone formation
serum marker PINP three days after treatment (PBS: 281.02 ng/mL
vs. ZOL: 65.62 ng/mL, p ≤ 0.01; Fig. 4E). In line with this, osteoblast
number/mm bone surface decreased signiﬁcantly from day 5 onwards
in ZOL treated animals, compared to PBS (day 5: PBS: 14.73 vs. ZOL:
6.62; p ≤ 0.05; day 10: PBS: 15.65 vs. ZOL: 5.66; p ≤ 0.01; Fig. 4F).
The data show that the signiﬁcant ZOL-induced changes in bone cell
number and activity are independent of the immune status of the
animals.
Visualisation of the zoledronic acid-induced osteoblast reduction in a
mouse model with GFP-positive osteoblastic cells
For the quantiﬁcation of osteoblasts, we identiﬁed the cells by
assessing their speciﬁc morphology as previously described [11]. In
addition, we used a model system where mice have been genetically
engineered to express GFP in cells of the osteoblastic lineage, facilitating
identiﬁcation andvisualisation of these cells. In these animals, the inhib-
itory effect of ZOL on osteoblastic cells was evident in tissues and histo-
logical sections (Fig. 5A) when compared to control. GFP staining
visualised that ZOL treatment predominantly altered osteoblastic cells/
mm bone surface in the trabecular bone area while the cell density
around the growth plate and the cortical bone was unaffected (Fig. 5B).
Toluidine blue staining showed that zoledronic acid appeared to increase
the amount of proteoglycan rich matrix in the metaphysis, and this
stretched deeper into the extending front of the growth plate comparedbalb/c nude mice were injected with zoledronic acid (100 μg/kg, i.p.) or PBS to assess the
measured in serumby TRAP ELISA, (D) osteoclast number permm trabecular bone surface,
abecular bone surface. Animalswere culled 3, 5 and 10 days post treatment. n= 3/day PBS
test: ****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05. All graphs show mean ± SEM.
Fig. 5. Conﬁrmation of ZOL-effects on GFP-expressing osteoblastic cells in a genetically engineered mouse model. (A) Reduction of GFP signal in tibia, femur, ribcages and rib sections of
a ZOL treated mouse compared to control. Arrows indicate the osteoblast rich growth plate area. (B) The reduction in osteoblasts on trabeculi can also be seen by GFP-
immunohistochemistry on parafﬁn sections of the tibia of 6-week old mice. Osteoblastic cells are stained brown, scale bar = 500 μm. Quantiﬁcation of osteoblasts by morphology
or after GFP-immunohostochemistry in (C) 6-week old mice (n = 2/group) and (D) 9–10-week old animals (n = 2/group) 5 days after a single injection of ZOL (100 μg/kg, i.p) or
PBS. Bottom panel (E) shows toluidine blue staining of proteoglycan in bone, scale bar = 300 μm.
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therefore be a result of elevated endochondral ossiﬁcation, as this excess
matrix is normally resorbed by osteoclasts.
In a small number of animals (n = 2/treatment group) we com-
pared whether quantiﬁcation of osteoblasts identiﬁed by morphology
or GFP-immunohistochemistry results in comparable data sets.
Both methods conﬁrmed the reduction in osteoblasts on trabecular
bone 5 days post ZOL injection when compared to control in
6 week-old mice (morphology on H&E: PBS: 2.77 vs. ZOL: 0.17;
GFP-immunohistochemistry: PBS: 2.46 vs. ZOL: 0.22; Fig. 5C). Ani-
mals with a more mature skeleton and thus lower bone turnover
(9–10 week-old, n= 2/group) also showed a reduction in osteoblast
number/mm trabecular bone surface (morphology on H&E: PBS:
2.59 vs. ZOL: 0.48, GFP-immunohistochemistry: PBS: 2.65 vs. ZOL:
0.49 Fig. 5D).
Our data demonstrate a rapid ZOL-induced drop in osteoblasts/mm
bone surface, accompanied by changes in the extra-cellular matrix of
the growth plate that in combination may alter the composition of the
bone metastasis niche.Effects of zoledronic acid on tumour cell homing to bone
Next we investigated whether the signiﬁcant ZOL-induced changes
to the bone microenvironment would inﬂuence subsequent tumour
cell homing to bone. Importantly, our experiments were carefully
designed to ensure that tumour cell arrival coincided with the time
point when the bone effects had reached their peak. In separate studies
using the same model we have established that tumour cells home to
bone within 24 h of intracardiac injection. Animals were pre-treated
with a single dose of ZOL (100 μg/kg, i.p.) 5 days before intracardiac in-
jection of DID-labelled tumour cells, and the presence of tumour cells in
bone marrow, blood and a number of other organs was determined.
Analysis of two separate experiments (n = 4/treatment group for
each experiment) suggested a reduction in the number of tumour
cells per millilitre blood in ZOL treated animals compared to those
receiving PBS (Experiment 1: PBS: 163.27/mL vs. ZOL: 1.09/mL,
Fig. 6A; Experiment 2: PBS: 290/mL vs. ZOL: 27.14/mL, Fig. 6C). To inves-
tigate whether ZOL treatment caused the tumour cells to localise to
other (non-bone) sites we prepared ex vivo cultures of soft tissue cell
Fig. 6. Effects of ZOL-induced alterations to the bonemicroenvironment on tumour cell homing to bone. Two separate experiments (n= 4/treatment group)were carried out to assess the
effects of a single dose of ZOL (100 μg/kg) or PBS on tumour cell homing to bone (experiment outline Fig. 1B).Whole blood (A, C) and bonemarrow (B,D)was collected, pooled for animals
within one experiment for each treatment group and the number of DID+ tumour cells assessed by ﬂow cytometry. (E) Illustrates the regions of interest (ROI) used for analysis of tumour
cells in bone by multiphoton analysis. The number of DID+ events in each ROI is shown in (F) for PBS and in (G) for ZOL treated mice. Student's t-test, graphs show mean ± SEM.
(H) Representative multiphoton scans showing bone (white) and DID + events (red).
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cells using antibiotic pressure in vitro. Tumour cells could only be
detected in the lung culture of one out of four animals of the ZOL
group. Pre-treatment with a single dose of ZOL did not greatly affect
the percentage of tumour cells in bone when assessed by ﬂow cytome-
try (PBS: 0.018% vs. ZOL: 0.028%, Fig. 6B; PBS: 0.005% vs. ZOL: 0.007%,
Fig. 6D). Since we had shown earlier that ZOL administration predomi-
nantly affects osteoblastic cells/mm trabecular bone, but osteoblasts are
still visible in the dense growth plate (Fig. 5B), we mapped the location
of tumour cells to different areas in the bone usingmultiphotonmicros-
copy. Three different regions of interest (ROI) were analysed including
the growth plate (ROI-2), trabecular bone (ROI-3) and the total
analysed area (ROI-1 = ROI-2 + ROI-3, Fig. 6E). Cortical bone was
excluded and data from two separate experiments was combined for
this analysis (n = 6/treatment group). Comparison of tumour cells
assessed by the total number of DID+ events in ROI-1 showed no dif-
ference between PBS and ZOL treated mice (PBS: 504.68 vs. ZOL:
501.10, p = 0.9799, Figs. 6F and G), conﬁrming the ﬂow cytometry
data. However, in control animals more DID+ events were detected
in the trabecular bone area (ROI-3) compared to the growth plate
(ROI-2) (ROI-2: 113.65 vs. ROI-3: 391.03, p= 0.0625, Fig. 6F) although
this did not reach statistical signiﬁcance. In contrast, ZOL-inducedalteration of the bone before tumour cell injection appeared to blunt
this preferential distribution (ROI-2: 208.67 vs. ROI-3: 292.44, p =
0.2959, Fig. 6G). Fig. 6Hdepicts representativemultiphoton scans show-
ing the bone structure as well as DID+ events.
The data indicate that pre-treatment with the bisphosphonate
reduced the number of circulating tumour cells, appeared to induce
changes in the distribution of tumour cells within bone but did not
affect overall number of tumour cells homing to bone. However, more
independent experiments are required to validate these results.
Discussion
In this study we have established how a single, clinically relevant,
dose of the anti-resorptive agent zoledronic acid modiﬁes key cells
of the bone microenvironment, suggested to be components of the
metastatic niche. Although osteoclasts and osteoblasts have been
shown to be part of the vicious cycle in late stage bone metastasis [23]
it remains to be established whether these cell types also regulate
cancer cell homing and/or trigger subsequent tumour cell proliferation.
Bisphosphonates (BPS) are standard of care in the treatment of cancer-
induced bone disease and are also proposed to exhibit direct and/or
indirect anti-tumour effects in vivo [24,25]. Clinical trials of adjuvant
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bone metastases. A recent update of the AZURE trial showed that
adjuvant treatment with ZOL, in addition to standard care in patients
at high-risk of developing breast cancer bone metastasis, reduced the
incidence of relapse in bone, demonstrating the beneﬁcial effects of
early ZOL treatment [12]. Although the underlying mechanisms remain
to be established, these may include a reduction in the survival and/or
progression of disseminated tumour cells in bone. This is supported by
data obtained in model systems, showing that preventive regimens
(i.e. administration of BPs prior to or at the time of tumour cell injection)
appearmore effective compared to therapeutic treatment of established
tumours [24]. However, the focus of most preventive in vivo studies has
been on reduction of tumour burden and the associated bone disease,
without assessing the effects that alterations to the bone microenviron-
ment may have for the subsequent tumour cell homing. In particular,
the potential consequences of BP treatment on osteoblasts have not
been investigated in this context. If osteoblasts are key components of
themetastatic niche, BP-induced changes to their number and/or activ-
ity may in turn affect tumour cell homing to the niche. We have there-
fore characterised the early effects of a single, clinically relevant, dose
of the potent BP zoledronic acid (ZOL) on osteoclasts and osteoblasts,
both of whichmay be inﬂuencing tumour cell homing and progression.
Importantly, we performed a detailed histomorphometric analysis of
ZOL effects on trabecular bone in the tibial metaphysis, as this region
is preferentially colonised by breast cancer cells in bone metastasis
models [11,22].
Whereas long-term, repeated treatment with BPs is shown to result
in a reduction of osteoclast activity [26–28] the acute effects of BPs on
this cell type in vivo have not previously been described in much detail.
Here we have shown that a single dose of ZOL inhibits bone resorption
as early as 3 days after in vivo administration, demonstrating that re-
peated treatment cycles are not required for initiation of bone effects.
The ZOL-induced changes to the osteoclasts were rapid and transient
for some parameters, highlighting the importance of measuring both
cell numbers and activity over time. The contradictory reports of ZOL ef-
fects on osteoclasts may be due to varying treatment schedules, model
systems and the end pointsmeasured. However, it is generally accepted
that repeated treatmentwith BPs inhibit osteoclast activity [26–28] and
alter osteoclastmorphology [29], resulting in increased bone volume. In
agreement with this, we found a rapid increase in bone volume accom-
panied by a decrease in TRAP serum levels and increase in osteoclast
size caused by a single administration of ZOL. The substantial effects of
BPs on osteoclasts are commonly suggested to be themajormechanism
of action behind their anti-tumour capacity [24]. However, ZOL has also
been shown to exhibit signiﬁcant anti-tumour effects in amodel system
using animals that lack functional osteoclasts, supporting that mecha-
nisms other than reduction of osteoclastic bone resorption are involved
in modifying tumour growth in bone [30].
Despite the close coupling between osteoclasts and osteoblasts, and
their proposed role in themetastatic niche, few studies have investigat-
ed the effects of anti-resorptive agents on osteoblastic cells. We found
a rapid ZOL-induced decrease in osteoblastic cells on trabecular bone
surfaces, but were unable to establish whether this was due to a direct
effect on the osteoblasts, or indirectly via osteoclast coupling. How
BPs affect osteoblastic cells is not fully understood. Very low (nano-
to pico-molar) concentrations of BPS are reported to cause increased
osteoblast differentiation in vitro [20,21,31], and protect against
glucocorticoid-induced apoptosis of osteoblasts and osteocytes both
in vitro [32] and in vivo [33]. A number of in vitro studies have shown
that long-term incubation of osteoblasts with high concentrations of
BPs induced apoptosis and/or impaired proliferation [15–18]. However,
the in vivo relevance of these studies is unclear. Due to the high bone
afﬁnity and rapid clearance of NBPs from the circulation, cells other
than actively resorbing osteoclasts are only exposed to the drug
for short times and at low concentrations following administration
in vivo. A study by Idris et al. [17] reported that a single dose ofalendronate increased levels of unprenylated Rap1a in calvarial osteo-
blasts at 24 h, suggesting direct uptake of the BP in vivo. However,
whether drug uptake was sufﬁcient to affect cell activity/number was
not determined. In support of our ﬁndings, osteoclast and osteoblast ac-
tivity is shown to be signiﬁcantly reduced compared to control after
3 weeks of ZOL treatment (0.05–1 mg/kg) in vivo, with a trend towards
a decrease in cell number [34]. In addition, we have previously reported
a signiﬁcant reduction in osteoblast number 13 days after a single injec-
tion of 100 μg/kg ZOL in vivo [35]. Importantly, the rapid manifestation
of the bone effects identiﬁed in the current study suggests that even a
brief exposure to this potent agentmay be sufﬁcient to generate biolog-
ical effects in vivo. Although we included a range of time points in this
study including 1 and 3 days after treatmentwe could not ﬁnd evidence
of increased cell death after ZOL treatment in either TRAP stained sec-
tions or in sections with GFP positive osteoblastic cells.
In addition to identifying ZOL-induced effects on the number and ac-
tivity of key bone cell types, we also found substantial changes in the
matrix content of the growth plate. During bone development, pre-
hypertrophic chondrocytes in the growth plate produce large amounts
of extra-cellular matrix (mainly proteoglycan), which is followed by
modelling and mineralisation by hypertrophic chondrocytes. At this
stage the hypertrophic cells die, enabling the entry of cells of the ossiﬁ-
cation centre including osteoclasts, osteoblasts and endothelial cells
[36]. BPs are reported to cause an elongation of the growth plate,
suggesting that osteoclasts are required for the degradation of the
cartilage matrix [37]. Interestingly, development of blood vessels
precedes the invasion of osteoclasts around the chondro-osseous
junction, which may facilitate extravasation of tumour cells to this
area. We found that ZOL treatment appeared to result in accumula-
tion of excess extracellular matrix resulting in a dramatic effect on
the physical environment of the growth plate. This could affect the
availability of soluble factors, as well as result in physical entrap-
ment of tumour cells homing to this area. In ZOL treated animals,
the remaining osteoblasts were predominantly located within the
increased ECM of the growth plate, with potential consequences for
the location of an osteoblastic niche.
The signiﬁcant reduction in osteoclasts and osteoblastic cells, aswell
as the changes in extracellularmatrix in the growth plate 3–5 days after
ZOL administration, leads us to hypothesise that this could cause amod-
iﬁcation of the metastatic niche and thus potentially inﬂuence tumour
cell homing. Taking a novel approach to test this, we used multiphoton
microscopy to quantify homing of tumour cells to different regions of
the metaphysis, and assessed how this was modiﬁed by ZOL. When
tumour cells were injected in animals where the putative niche area
had beenmodiﬁed by pre-treatmentwith ZOL, their location and distri-
bution appeared to be altered compared to that in control bones. We
found a trend towards enrichment of tumour cells in the same region
of the metaphysis where ZOL had induced accumulation of ECM, and
where the majority of the osteoblasts were now located. This intriguing
ﬁnding needs veriﬁcation in independent studies, but may indicate that
particular ‘preferred’ osteoblast-rich niche areas are present within
the metaphysis. The mapping of tumour cells to speciﬁc areas of bone
is technically challenging and it remains to be established how other
elements inﬂuencing tumour cell homing to bone are modiﬁed by
ZOL, including those of the vascular niche.
Despite inducing a trend towards altered tumour cell location, ZOL
treatment did not reduce the total number of tumour cells in bone.
The percentage of circulating tumour cells appeared dramatically
reduced; however, the fate of circulating tumour cells after ZOL pre-
treatment remains to be established and effects on tumour cell homing
and growth in bone should be established using repeated dosing
experiments.
The ﬁndings suggest that a single drug administration is not sufﬁ-
cient to prevent tumour development and progression. This is in agree-
ment with results reported by Daubine et al. [38], investigating the
effects of preventive ZOL dosing regimens on B02 breast tumour growth
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change in tumour burden in bone on day 14, or reduce the area of
osteolytic lesions or skeletal tumour burden present by day 32. Both
daily andweekly regimenswere beneﬁcial for all these parameters, sug-
gesting that repeated dosing with ZOL is required to prevent tumour
progression in bone. In support of this, repeated treatment with ZOL is
shown to increase elimination of disseminated breast cancer cells in
breast cancer patients [39,40].
Conclusion
In summary, this study presents novel evidence that a single dose of
zoledronic acid rapidly induces signiﬁcant alterations to both the cellu-
lar component and the extra-cellularmatrix of themetaphysis, the area
of bone comprising the metastatic niche. Although total tumour cell
number in bone was not altered there was a trend towards accumula-
tion in osteoblast-rich areas after ZOL treatment. This is theﬁrst demon-
stration that breast cancer cells appear to preferentially localise to
speciﬁc regions of the metaphysis, but that they may home to other
areas if challenged by a modiﬁed microenvironment. Our data support
that osteoblasts are a key component of the metastatic niche.
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